 Fatty Liver Disease: NASH and Related Disorders
ISBN: 978-1-4051-1292-5
Hardcover
336 pages
December 2004, Wiley-Blackwell
US $159.95
 Add to Cart
This price is valid for United States. Change location to view local pricing and availability. This is a Print-on-Demand title. It will be printed specifically to fill your order. Please allow an additional 1-2 days delivery time for paperbacks, and 3-5 days for hardcovers. The book is not returnable.
Other Available Formats: Adobe E-Book
|
An online version of this product is available through our subscription-based content service. Visit Wiley InterScience now |
Contributors.
Preface.
1 Overview: an introduction to NASH and related fatty liver disorders.
2 Pathology of hepatic steatosis, NASH and related conditions.
3 The epidemiology and risk factors of NASH.
4 Insulin resistance in NAFLD: potential mechanisms and therapies.
5 NASH as part of the metabolic (insulin resistance) syndrome.
6 NASH is a genetically determined disease.
7 The pathogenesis of NASH: human studies.
8 Animal models of steatohepatitis.
9 Fatty acid metabolism and lipotoxicity in the pathogenesis of NAFLD/NASH.
10 Cytokines and inflammatory recruitment in NASH: experimental and human studies.
11 Mitochondrial injury and NASH.
12 Cell biology of NASH: fibrosis and cell proliferation.
13 Clinical manifestations and diagnosis of NAFLD.
14 The clinical outcome of NAFLD including cryptogenic cirrhosis.
15 Practical approach to the diagnosis and management of people with fatty liver diseases.
16 Management of NASH: current and future perspectives on treatment.
17 NAFLD, NASH and orthotopic liver transplantation.
18 NAFLD/NASH is not just a 'Western' problem: some perspectives on NAFLD/NASH from the East.
19 NAFLD/NASH in children.
20 Steatohepatitis resulting from intestinal bypass.
21 Specific disorders associated with NAFLD.
22 Hepatocellular carcinoma in NAFLD.
23 Does NASH or NAFLD contribute to comorbidity of other liver diseases?.
24 Recent advances.
Index
Preface.
1 Overview: an introduction to NASH and related fatty liver disorders.
2 Pathology of hepatic steatosis, NASH and related conditions.
3 The epidemiology and risk factors of NASH.
4 Insulin resistance in NAFLD: potential mechanisms and therapies.
5 NASH as part of the metabolic (insulin resistance) syndrome.
6 NASH is a genetically determined disease.
7 The pathogenesis of NASH: human studies.
8 Animal models of steatohepatitis.
9 Fatty acid metabolism and lipotoxicity in the pathogenesis of NAFLD/NASH.
10 Cytokines and inflammatory recruitment in NASH: experimental and human studies.
11 Mitochondrial injury and NASH.
12 Cell biology of NASH: fibrosis and cell proliferation.
13 Clinical manifestations and diagnosis of NAFLD.
14 The clinical outcome of NAFLD including cryptogenic cirrhosis.
15 Practical approach to the diagnosis and management of people with fatty liver diseases.
16 Management of NASH: current and future perspectives on treatment.
17 NAFLD, NASH and orthotopic liver transplantation.
18 NAFLD/NASH is not just a 'Western' problem: some perspectives on NAFLD/NASH from the East.
19 NAFLD/NASH in children.
20 Steatohepatitis resulting from intestinal bypass.
21 Specific disorders associated with NAFLD.
22 Hepatocellular carcinoma in NAFLD.
23 Does NASH or NAFLD contribute to comorbidity of other liver diseases?.
24 Recent advances.
Index
